These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 14752083

  • 1. HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear?
    Ferretti G, Di Cosimo S, Giannarelli D, Carlini P, Papaldo P, Alimonti A, Fabi A, Mandalà M, Milella M, Ruggeri EM, Cognetti F.
    J Clin Oncol; 2004 Feb 01; 22(3):568-9. PubMed ID: 14752083
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Sensitivity of chemotherapy depending on hormone status in breast cancer].
    Ito Y.
    Nihon Rinsho; 2007 Jun 28; 65 Suppl 6():568-71. PubMed ID: 17679212
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Co-expression of steroid hormone receptors (estrogen receptor alpha and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer: clinical outcome following tamoxifen-based adjuvant therapy.
    Gago FE, Fanelli MA, Ciocca DR.
    J Steroid Biochem Mol Biol; 2006 Jan 28; 98(1):36-40. PubMed ID: 16188438
    [Abstract] [Full Text] [Related]

  • 8. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
    Tokunaga E, Kataoka A, Kimura Y, Oki E, Mashino K, Nishida K, Koga T, Morita M, Kakeji Y, Baba H, Ohno S, Maehara Y.
    Eur J Cancer; 2006 Mar 28; 42(5):629-35. PubMed ID: 16464571
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy.
    D'Alessandro C, Dellapasqua S, Orlando L, Santoro L, Maisonneuve P, Torrisi R, Balduzzi A, Scarano E, Ghisini R, Peruzzotti G, Goldhirsch A, Colleoni M.
    Breast J; 2008 Mar 28; 14(5):435-41. PubMed ID: 18821931
    [Abstract] [Full Text] [Related]

  • 11. RE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.
    Sgroi DC, Haber DA, Ryan PD, Ma XJ, Erlander MG.
    Cancer Cell; 2004 Nov 28; 6(5):445. PubMed ID: 15542428
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Gene expression profiles of the oestrogen receptor in breast cancer.
    Kok M, Linn SC.
    Neth J Med; 2010 Oct 28; 68(10):291-302. PubMed ID: 21071774
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Prediction for efficacy of endocrine therapy for breast cancers using gene profiling].
    Iwase H, Yamamoto Y.
    Nihon Rinsho; 2007 Jun 28; 65 Suppl 6():549-54. PubMed ID: 17682209
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen.
    Muss HB, Bunn JY, Crocker A, Plaut K, Koh J, Heintz N, Rincon M, Weaver DL, Tam D, Beatty B, Kaufman P, Donovan M, Verbel D, Weiss L.
    Breast J; 2007 Jun 28; 13(4):337-45. PubMed ID: 17593037
    [Abstract] [Full Text] [Related]

  • 20. Endocrine therapy for early breast cancer.
    Hussain SA, Williams S, Stevens A, Rea DW.
    Expert Rev Anticancer Ther; 2004 Oct 28; 4(5):877-88. PubMed ID: 15485321
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.